Chadha, M. http://orcid.org/0000-0002-9194-1839
White, J.
Swain, S. M. http://orcid.org/0000-0002-1320-3830
Rakovitch, E.
Jagsi, R.
Whelan, T. http://orcid.org/0000-0001-9844-2023
Sparano, J. A. http://orcid.org/0000-0002-9031-2010
Article History
Received: 31 May 2023
Accepted: 6 October 2023
First Online: 14 December 2023
Competing interests
: S.S.: Honoraria for consulting/advisory boards in the past 2 years: AstraZeneca, Daiichi-Sankyo, Natera, Biotheranostics, Molecular Templates, Sanofi; non-promotional speaking: Genentech/Roche; research funding to institution: Genentech/Roche, Kailos Genetics; third party in kind writing: AstraZeneca and Genentech/Roche; travel in kind: Genentech/Roche, Daiichi Sankyo, Sanofi; SEAGEN Board of Directors with stock, stipend, and travel; Napo Pharmaceuticals Scientific Advisory Board: stipend and travel; American Society of Clinical Oncology Conquer Cancer Foundation Board of Directors, unpaid; National Surgical Breast and Bowel Project Foundation Board of Directors, unpaid; R.J.: Effort on this work was supported by a Senior Scholar Grant from the Susan G. Komen Foundation. Unrelated to the current work, R.J. has stock options as compensation for her advisory board role in Equity Quotient, a company that evaluates culture in health care companies; she has received personal fees from the Greenwall Foundation, Doris Duke Charitable Foundation, and the National Institutes of Health and grants or contracts for unrelated work from the National Institutes of Health, the Doris Duke Charitable Foundation, and the American Cancer Society. She has served as an expert witness for Dressman Benzinger LaVelle and Kleinbard, LLC. T.W.: Exact sciences—non-direct financial support for biomarker testing for ongoing studies unrelated to this work. J.A.S.: Associate Editor of <i>npj</i><i>Breast Cancer</i>. The other authors declare no competing interests.